Weihao Xu

Matthews International Capital Management LLC (dba Matthews Asia) is an independent SEC-registered investment advisor and mutual fund manager headquartered in San Francisco, California. The firm was founded by Paul Matthews in 1991. Matthews Asia manages portfolios for institutional clients, pension and profit-sharing plans, insurance companies, endowments and foundations and other business entities around the world. Institutional clients include funds registered under the laws of Luxembourg, United Kingdom, Ireland and Canada.

Matthews International Capital Management LLC (dba Matthews Asia) is an independent SEC-registered investment advisor and mutual fund manager headquartered in San Francisco, California. The firm was founded by Paul Matthews in 1991. Matthews Asia manages portfolios for institutional clients, pension and profit-sharing plans, insurance companies, endowments and foundations and other business entities around the world. Institutional clients include funds registered under the laws of Luxembourg, United Kingdom, Ireland and Canada.

The Permal Group Ltd. provides asset management services. It offers multi-manager and single manager funds, separate accounts and structured products. The company is headquartered in New York, NY.

Lansdowne Partners (UK) LLP (Lansdowne) is the alternative investment management subsidiary of Lansdowne Partners Ltd., itself a subsidiary of Lansdowne Partners International Ltd. in the Cayman Islands. The firm is headquartered in London and was founded in 1998. Lansdowne provides investment advisory services on a discretionary basis to their clients, which includes commingled investment vehicles intended for institutional investors and other sophisticated investors and investment vehicles formed for particular investors and separately managed accounts for sophisticated financial institutions, including registered investment companies. Lansdowne is a signatory to the United Nations Principles of Responsible Investing (UNPRI).

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.